No bearish signal. The sales are routine portfolio rebalancing by non-C-suite executives following vesting/exercise of derivatives, occurring after a strong earnings beat. Ignore this cluster.
LH drugs
LH drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 6 $316.53entry
- T+1 · 3mo ago +0.83%α +0.22% · $319.17
- T+5 · 3mo ago +1.91%α +0.70% · $322.59
- T+20 · 3mo ago +4.73%α +4.13% · $331.50
- T+60 · 18d ago +14.17%α +15.84% · $361.39
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two insiders at Labcorp sold shares shortly after the company reported a strong Q2 beat and raised guidance. Total open-market sales of ~$309K represent under 0.001% of market cap, making the cluster economically trivial. The sales are likely liquidity-driven following derivative exercises and are not a negative signal against solid fundamentals.
Key Financial Metrics
Key Facts
- EVP Amy Summy sold 924 shares open-market for ~$283K on Aug 4
- SVP Peter Wilkinson sold 1,338 shares open-market for ~$414K on Aug 3 after exercising derivative options
- Total open-market sales: ~$697K, or ~0.003% of Labcorp's $26B market cap
- Non-cash derivative exercises by Wilkinson (1,338 shares at $0) generated no economic value
- Recent Q2 earnings (Jul 30) beat consensus, guidance raised, and buyback authorization increased by $1B
Financial Impact
Insider sales totaling ~$697K, representing 0.003% of market cap, immaterial
Risk Factors
- None from this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-LH-1786083417391 |
Track record
29 reports on LH
5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +17.60% at T+60 after the Apr 30, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $372.32 Now $372.46 +0.04% settles Nov 19
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $372.23 Now $372.46 +0.06% settles Nov 18
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $363.30 to $372.32 Now $372.46 +2.52% ▲ +2.48% −0.81% vs SPY
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $367.79 to $372.23 Now $372.46 +1.27% ▲ +1.21% +2.12% vs SPY
- Nov 4, 202612d ago 8-K Neutral 2/10 Entry $367.79 to $372.23 Now $372.46 +1.27% ▲ +1.21% +2.12% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $353.92 to $370.88 Now $372.46 +5.24% ▲ +4.79% +5.38% vs SPY
- Oct 30, 202617d ago 144 Neutral 2/10 Entry $361.39 to $366.57 Now $372.46 +3.06% ▲ +1.43% +4.14% vs SPY
- Oct 28, 202619d ago 8-K Bullish 6/10 Entry $360.25 to $367.79 Now $372.46 +3.39% ▲ +2.09% +2.81% vs SPY
- Oct 26, 202621d ago Institutional Cluster Neutral 3/10 Entry $329.90 to $361.39 Now $372.46 +12.90% ▲ +9.55% +10.81% vs SPY
- Oct 21, 202626d ago 8-K Neutral 2/10 Entry $323.75 to $331.17 Now $372.46 +15.05% ▲ +2.29% +2.74% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers